JP2014521623A - Ｊａｋ阻害剤としてのヘテロシクリルピリミジンアナログ - Google Patents

Info

Publication number

JP2014521623A

JP2014521623A JP2014522067A JP2014522067A JP2014521623A JP 2014521623 A JP2014521623 A JP 2014521623A JP 2014522067 A JP2014522067 A JP 2014522067A JP 2014522067 A JP2014522067 A JP 2014522067A JP 2014521623 A JP2014521623 A JP 2014521623A

Authority

JP

Japan

Prior art keywords

amino

pyrazol

pyrimidin

chloro

hydroxyethyl

Prior art date

2011-07-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• -1 Heterocyclyl pyrimidine analogs Chemical class 0.000 title claims description 65
• 229940122245 Janus kinase inhibitor Drugs 0.000 title abstract description 7
• 150000001875 compounds Chemical class 0.000 claims abstract description 146
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 58
• 201000010099 disease Diseases 0.000 claims abstract description 32
• 238000011282 treatment Methods 0.000 claims abstract description 22
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
• 239000003814 drug Substances 0.000 claims abstract description 17
• 230000002757 inflammatory effect Effects 0.000 claims abstract description 10
• 230000000172 allergic effect Effects 0.000 claims abstract description 9
• 208000010668 atopic eczema Diseases 0.000 claims abstract description 9
• 230000001363 autoimmune Effects 0.000 claims abstract description 9
• 230000001900 immune effect Effects 0.000 claims abstract description 8
• 125000000217 alkyl group Chemical group 0.000 claims description 87
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 59
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 57
• 238000000034 method Methods 0.000 claims description 56
• 150000003839 salts Chemical class 0.000 claims description 54
• 229910052799 carbon Inorganic materials 0.000 claims description 52
• 229910052736 halogen Inorganic materials 0.000 claims description 44
• 229910052739 hydrogen Inorganic materials 0.000 claims description 43
• 150000002367 halogens Chemical class 0.000 claims description 36
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
• 208000035475 disorder Diseases 0.000 claims description 25
• 230000000155 isotopic effect Effects 0.000 claims description 22
• 125000000623 heterocyclic group Chemical group 0.000 claims description 20
• 229920006395 saturated elastomer Polymers 0.000 claims description 20
• 229910052757 nitrogen Inorganic materials 0.000 claims description 17
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 13
• 206010052779 Transplant rejections Diseases 0.000 claims description 11
• 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 10
• 208000024908 graft versus host disease Diseases 0.000 claims description 10
• 208000037765 diseases and disorders Diseases 0.000 claims description 9
• 230000002062 proliferating effect Effects 0.000 claims description 9
• 208000009329 Graft vs Host Disease Diseases 0.000 claims description 8
• 125000005843 halogen group Chemical group 0.000 claims description 8
• 239000003937 drug carrier Substances 0.000 claims description 7
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
• 238000004519 manufacturing process Methods 0.000 claims description 6
• 125000000304 alkynyl group Chemical group 0.000 claims description 5
• 229910052731 fluorine Inorganic materials 0.000 claims description 5
• HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 4
• 229910052801 chlorine Inorganic materials 0.000 claims description 4
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 4
• QCIINRKCNBJUQL-OAHLLOKOSA-N 2-[4-[[5-chloro-4-[[(1s)-2-hydroxy-1-phenylethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=CC=CC=2)=N1 QCIINRKCNBJUQL-OAHLLOKOSA-N 0.000 claims description 3
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
• YWAUQSFUTBZFMJ-CQSZACIVSA-N (2s)-2-(2,5-difluorophenyl)-2-[[5-fluoro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(F)C(N[C@H](CO)C=2C(=CC=C(F)C=2)F)=N1 YWAUQSFUTBZFMJ-CQSZACIVSA-N 0.000 claims description 2
• MJELYOPKYYXACK-OAHLLOKOSA-N (2s)-2-(2,5-difluorophenyl)-2-[[5-methyl-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]ethanol Chemical compound N1=C(N[C@H](CO)C=2C(=CC=C(F)C=2)F)C(C)=CN=C1NC=1C=NN(C)C=1 MJELYOPKYYXACK-OAHLLOKOSA-N 0.000 claims description 2
• FFCIMDGIZAZOGN-CQSZACIVSA-N (2s)-2-(3,5-difluorophenyl)-2-[[5-fluoro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(F)C(N[C@H](CO)C=2C=C(F)C=C(F)C=2)=N1 FFCIMDGIZAZOGN-CQSZACIVSA-N 0.000 claims description 2
• QAEHLBSLFWONBV-OAHLLOKOSA-N (2s)-2-(3,5-difluorophenyl)-2-[[5-fluoro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(F)C(N[C@H](CO)C=2C=C(F)C=C(F)C=2)=N1 QAEHLBSLFWONBV-OAHLLOKOSA-N 0.000 claims description 2
• YOOXDLOGFFYUFG-OAHLLOKOSA-N (2s)-2-(3,5-difluorophenyl)-2-[[5-methyl-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]ethanol Chemical compound N1=C(N[C@H](CO)C=2C=C(F)C=C(F)C=2)C(C)=CN=C1NC=1C=NN(C)C=1 YOOXDLOGFFYUFG-OAHLLOKOSA-N 0.000 claims description 2
• YUDWGAZWJTYIHS-OAHLLOKOSA-N (2s)-2-(3-bromo-5-fluorophenyl)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=C(Br)C=C(F)C=2)=N1 YUDWGAZWJTYIHS-OAHLLOKOSA-N 0.000 claims description 2
• ALZYRQUSZSTJID-CQSZACIVSA-N (2s)-2-(3-bromo-5-fluorophenyl)-2-[[5-fluoro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(F)C(N[C@H](CO)C=2C=C(Br)C=C(F)C=2)=N1 ALZYRQUSZSTJID-CQSZACIVSA-N 0.000 claims description 2
• JEHPGIJIBVMJLS-OAHLLOKOSA-N (2s)-2-(3-bromo-5-fluorophenyl)-2-[[5-fluoro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(F)C(N[C@H](CO)C=2C=C(Br)C=C(F)C=2)=N1 JEHPGIJIBVMJLS-OAHLLOKOSA-N 0.000 claims description 2
• CANMIUFARMZZQH-CQSZACIVSA-N (2s)-2-(3-bromophenyl)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=C(Br)C=CC=2)=N1 CANMIUFARMZZQH-CQSZACIVSA-N 0.000 claims description 2
• NGIMWXFLGMKNKL-OAHLLOKOSA-N (2s)-2-(3-bromophenyl)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=C(Br)C=CC=2)=N1 NGIMWXFLGMKNKL-OAHLLOKOSA-N 0.000 claims description 2
• ODUGFSPAXUTPGE-OAHLLOKOSA-N (2s)-2-(3-bromophenyl)-2-[[5-methyl-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]ethanol Chemical compound N1=C(N[C@H](CO)C=2C=C(Br)C=CC=2)C(C)=CN=C1NC=1C=NN(C)C=1 ODUGFSPAXUTPGE-OAHLLOKOSA-N 0.000 claims description 2
• JJRIDVJZTBQPTI-CQSZACIVSA-N (2s)-2-[[2-[(1-methylpyrazol-4-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]-2-phenylethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(C(F)(F)F)C(N[C@H](CO)C=2C=CC=CC=2)=N1 JJRIDVJZTBQPTI-CQSZACIVSA-N 0.000 claims description 2
• WNQNFVMZAGNSOR-OAHLLOKOSA-N (2s)-2-[[2-[[1-(2,2-difluoroethyl)pyrazol-4-yl]amino]-5-methylpyrimidin-4-yl]amino]-2-(2,5-difluorophenyl)ethanol Chemical compound N1=C(N[C@H](CO)C=2C(=CC=C(F)C=2)F)C(C)=CN=C1NC=1C=NN(CC(F)F)C=1 WNQNFVMZAGNSOR-OAHLLOKOSA-N 0.000 claims description 2
• WCGNRXHZJZLUQM-OAHLLOKOSA-N (2s)-2-[[2-[[1-(2,2-difluoroethyl)pyrazol-4-yl]amino]-5-methylpyrimidin-4-yl]amino]-2-(3,5-difluorophenyl)ethanol Chemical compound N1=C(N[C@H](CO)C=2C=C(F)C=C(F)C=2)C(C)=CN=C1NC=1C=NN(CC(F)F)C=1 WCGNRXHZJZLUQM-OAHLLOKOSA-N 0.000 claims description 2
• ICCWXOGFMYSKGA-MRXNPFEDSA-N (2s)-2-[[2-[[1-(3-aminopropyl)pyrazol-4-yl]amino]-5-chloropyrimidin-4-yl]amino]-2-phenylethanol Chemical compound C1=NN(CCCN)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=CC=CC=2)=N1 ICCWXOGFMYSKGA-MRXNPFEDSA-N 0.000 claims description 2
• GHHPIJVNIUCRLD-CYBMUJFWSA-N (2s)-2-[[5-chloro-2-(1h-pyrazol-4-ylamino)pyrimidin-4-yl]amino]-2-(2-fluorophenyl)ethanol Chemical compound N([C@H](CO)C=1C(=CC=CC=1)F)C(C(=CN=1)Cl)=NC=1NC=1C=NNC=1 GHHPIJVNIUCRLD-CYBMUJFWSA-N 0.000 claims description 2
• ADQQOSPIQJDZIN-CYBMUJFWSA-N (2s)-2-[[5-chloro-2-(1h-pyrazol-4-ylamino)pyrimidin-4-yl]amino]-2-(3-fluorophenyl)ethanol Chemical compound N([C@H](CO)C=1C=C(F)C=CC=1)C(C(=CN=1)Cl)=NC=1NC=1C=NNC=1 ADQQOSPIQJDZIN-CYBMUJFWSA-N 0.000 claims description 2
• KKTWUGALTUFPNR-CYBMUJFWSA-N (2s)-2-[[5-chloro-2-(1h-pyrazol-4-ylamino)pyrimidin-4-yl]amino]-2-phenylethanol Chemical compound N([C@H](CO)C=1C=CC=CC=1)C(C(=CN=1)Cl)=NC=1NC=1C=NNC=1 KKTWUGALTUFPNR-CYBMUJFWSA-N 0.000 claims description 2
• WJTRZKOLMJCKOK-OAHLLOKOSA-N (2s)-2-[[5-chloro-2-[(1-ethylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(2-fluorophenyl)ethanol Chemical compound C1=NN(CC)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C(=CC=CC=2)F)=N1 WJTRZKOLMJCKOK-OAHLLOKOSA-N 0.000 claims description 2
• ZXSVYJNRLDWVSN-OAHLLOKOSA-N (2s)-2-[[5-chloro-2-[(1-ethylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(2-methoxyphenyl)ethanol Chemical compound C1=NN(CC)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C(=CC=CC=2)OC)=N1 ZXSVYJNRLDWVSN-OAHLLOKOSA-N 0.000 claims description 2
• YKQWFJMZPAGVCO-MRXNPFEDSA-N (2s)-2-[[5-chloro-2-[(1-ethylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(3-methoxyphenyl)ethanol Chemical compound C1=NN(CC)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=C(OC)C=CC=2)=N1 YKQWFJMZPAGVCO-MRXNPFEDSA-N 0.000 claims description 2
• SRXFYWKVPABCPB-CQSZACIVSA-N (2s)-2-[[5-chloro-2-[(1-ethylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-pyridin-3-ylethanol Chemical compound C1=NN(CC)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=NC=CC=2)=N1 SRXFYWKVPABCPB-CQSZACIVSA-N 0.000 claims description 2
• YKIWOVFZCRFHFX-CYBMUJFWSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-3-yl)amino]pyrimidin-4-yl]amino]-2-phenylethanol Chemical compound CN1C=CC(NC=2N=C(N[C@H](CO)C=3C=CC=CC=3)C(Cl)=CN=2)=N1 YKIWOVFZCRFHFX-CYBMUJFWSA-N 0.000 claims description 2
• NLBLZALOYCDNAW-CQSZACIVSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(2,5-difluorophenyl)ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C(=CC=C(F)C=2)F)=N1 NLBLZALOYCDNAW-CQSZACIVSA-N 0.000 claims description 2
• WNAVYYSDFDNZGV-CQSZACIVSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(2-fluorophenyl)ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C(=CC=CC=2)F)=N1 WNAVYYSDFDNZGV-CQSZACIVSA-N 0.000 claims description 2
• MMUMFSOUTIHSSK-CQSZACIVSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(2-methoxyphenyl)ethanol Chemical compound COC1=CC=CC=C1[C@@H](CO)NC1=NC(NC2=CN(C)N=C2)=NC=C1Cl MMUMFSOUTIHSSK-CQSZACIVSA-N 0.000 claims description 2
• RFIUFRRMSPKJFK-CQSZACIVSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(3,5-difluorophenyl)ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=C(F)C=C(F)C=2)=N1 RFIUFRRMSPKJFK-CQSZACIVSA-N 0.000 claims description 2
• IENUHAKGQXATMC-CQSZACIVSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(3-fluorophenyl)ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=C(F)C=CC=2)=N1 IENUHAKGQXATMC-CQSZACIVSA-N 0.000 claims description 2
• ZZIKCPQEINCIBY-OAHLLOKOSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(3-methoxyphenyl)ethanol Chemical compound COC1=CC=CC([C@@H](CO)NC=2C(=CN=C(NC3=CN(C)N=C3)N=2)Cl)=C1 ZZIKCPQEINCIBY-OAHLLOKOSA-N 0.000 claims description 2
• DEXQVSWVAHWJPK-GOSISDBHSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-[3-(1-methylpyrazol-4-yl)phenyl]ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=C(C=CC=2)C2=CN(C)N=C2)=N1 DEXQVSWVAHWJPK-GOSISDBHSA-N 0.000 claims description 2
• QOHXWGSDOSTOJA-GOSISDBHSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-[3-fluoro-5-(1-methylpyrazol-4-yl)phenyl]ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=C(C=C(F)C=2)C2=CN(C)N=C2)=N1 QOHXWGSDOSTOJA-GOSISDBHSA-N 0.000 claims description 2
• RXQRUYJJCNKFIQ-CQSZACIVSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-phenylethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=CC=CC=2)=N1 RXQRUYJJCNKFIQ-CQSZACIVSA-N 0.000 claims description 2
• VWLXZDUUVRDYGP-HNNXBMFYSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-n,n-dimethyl-2-phenylacetamide Chemical compound N([C@H](C(=O)N(C)C)C=1C=CC=CC=1)C(C(=CN=1)Cl)=NC=1NC=1C=NN(C)C=1 VWLXZDUUVRDYGP-HNNXBMFYSA-N 0.000 claims description 2
• WYKFXRHIIVPURK-HNNXBMFYSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-n-(2-hydroxyethyl)-2-phenylacetamide Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(N[C@H](C(=O)NCCO)C=2C=CC=CC=2)=N1 WYKFXRHIIVPURK-HNNXBMFYSA-N 0.000 claims description 2
• DHBOFEVPSKJZDG-INIZCTEOSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-n-(2-methoxyethyl)-2-phenylacetamide Chemical compound N([C@H](C(=O)NCCOC)C=1C=CC=CC=1)C(C(=CN=1)Cl)=NC=1NC=1C=NN(C)C=1 DHBOFEVPSKJZDG-INIZCTEOSA-N 0.000 claims description 2
• NUOFTMVVHQUZGO-SFHVURJKSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-n-cyclopentyl-2-phenylacetamide Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(N[C@H](C(=O)NC2CCCC2)C=2C=CC=CC=2)=N1 NUOFTMVVHQUZGO-SFHVURJKSA-N 0.000 claims description 2
• VAEZNBCTCPXOEY-HNNXBMFYSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-n-ethyl-2-phenylacetamide Chemical compound N([C@H](C(=O)NCC)C=1C=CC=CC=1)C(C(=CN=1)Cl)=NC=1NC=1C=NN(C)C=1 VAEZNBCTCPXOEY-HNNXBMFYSA-N 0.000 claims description 2
• IWCMSDDIRYMGNN-AWEZNQCLSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-n-methyl-2-phenylacetamide Chemical compound N([C@H](C(=O)NC)C=1C=CC=CC=1)C(C(=CN=1)Cl)=NC=1NC=1C=NN(C)C=1 IWCMSDDIRYMGNN-AWEZNQCLSA-N 0.000 claims description 2
• RSGVOJRSLUEJIB-MRXNPFEDSA-N (2s)-2-[[5-chloro-2-[(1-propan-2-ylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(2-fluorophenyl)ethanol Chemical compound C1=NN(C(C)C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C(=CC=CC=2)F)=N1 RSGVOJRSLUEJIB-MRXNPFEDSA-N 0.000 claims description 2
• YKLSOBAPDFODQO-MRXNPFEDSA-N (2s)-2-[[5-chloro-2-[(1-propan-2-ylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(2-methoxyphenyl)ethanol Chemical compound COC1=CC=CC=C1[C@@H](CO)NC1=NC(NC2=CN(N=C2)C(C)C)=NC=C1Cl YKLSOBAPDFODQO-MRXNPFEDSA-N 0.000 claims description 2
• KHDOTATXPPYSRM-QGZVFWFLSA-N (2s)-2-[[5-chloro-2-[(1-propan-2-ylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(3-methoxyphenyl)ethanol Chemical compound COC1=CC=CC([C@@H](CO)NC=2C(=CN=C(NC3=CN(N=C3)C(C)C)N=2)Cl)=C1 KHDOTATXPPYSRM-QGZVFWFLSA-N 0.000 claims description 2
• LAPQLBXPBRWDHE-OAHLLOKOSA-N (2s)-2-[[5-chloro-2-[(1-propan-2-ylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-pyridin-3-ylethanol Chemical compound C1=NN(C(C)C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=NC=CC=2)=N1 LAPQLBXPBRWDHE-OAHLLOKOSA-N 0.000 claims description 2
• VLVBFDWOLPFQSL-OAHLLOKOSA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-(2-fluorophenyl)ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C(=CC=CC=2)F)=N1 VLVBFDWOLPFQSL-OAHLLOKOSA-N 0.000 claims description 2
• AJBNNIRGRQTWJS-OAHLLOKOSA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-(2-methoxyphenyl)ethanol Chemical compound COC1=CC=CC=C1[C@@H](CO)NC1=NC(NC2=CN(CCO)N=C2)=NC=C1Cl AJBNNIRGRQTWJS-OAHLLOKOSA-N 0.000 claims description 2
• GZAUZHXRHFRDOK-OAHLLOKOSA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-(3,5-difluorophenyl)ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=C(F)C=C(F)C=2)=N1 GZAUZHXRHFRDOK-OAHLLOKOSA-N 0.000 claims description 2
• CKOSHJVGYPLDMB-OAHLLOKOSA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-(3-fluorophenyl)ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=C(F)C=CC=2)=N1 CKOSHJVGYPLDMB-OAHLLOKOSA-N 0.000 claims description 2
• WJIXMUBFHZXTCZ-MRXNPFEDSA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-(3-methoxyphenyl)ethanol Chemical compound COC1=CC=CC([C@@H](CO)NC=2C(=CN=C(NC3=CN(CCO)N=C3)N=2)Cl)=C1 WJIXMUBFHZXTCZ-MRXNPFEDSA-N 0.000 claims description 2
• IBNVHZOHLPFNTD-LJQANCHMSA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-[3-(1-methylpyrazol-4-yl)phenyl]ethanol Chemical compound C1=NN(C)C=C1C1=CC=CC([C@@H](CO)NC=2C(=CN=C(NC3=CN(CCO)N=C3)N=2)Cl)=C1 IBNVHZOHLPFNTD-LJQANCHMSA-N 0.000 claims description 2
• POVHSKOBBQQZRQ-LJQANCHMSA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-[3-fluoro-5-(1-methylpyrazol-4-yl)phenyl]ethanol Chemical compound C1=NN(C)C=C1C1=CC(F)=CC([C@@H](CO)NC=2C(=CN=C(NC3=CN(CCO)N=C3)N=2)Cl)=C1 POVHSKOBBQQZRQ-LJQANCHMSA-N 0.000 claims description 2
• XMNALHSLGADDHY-IBGZPJMESA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-phenyl-1-piperidin-1-ylethanone Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(N[C@H](C(=O)N2CCCCC2)C=2C=CC=CC=2)=N1 XMNALHSLGADDHY-IBGZPJMESA-N 0.000 claims description 2
• JGMJIRRCDLKALH-SFHVURJKSA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-phenyl-1-pyrrolidin-1-ylethanone Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(N[C@H](C(=O)N2CCCC2)C=2C=CC=CC=2)=N1 JGMJIRRCDLKALH-SFHVURJKSA-N 0.000 claims description 2
• WPKBELRPTDQFFT-OAHLLOKOSA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-phenylethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=CC=CC=2)=N1 WPKBELRPTDQFFT-OAHLLOKOSA-N 0.000 claims description 2
• FOFRZBWOODJWCY-CQSZACIVSA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-pyridin-2-ylethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2N=CC=CC=2)=N1 FOFRZBWOODJWCY-CQSZACIVSA-N 0.000 claims description 2
• OQPJLEVRKAILTG-CQSZACIVSA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-pyridin-3-ylethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=NC=CC=2)=N1 OQPJLEVRKAILTG-CQSZACIVSA-N 0.000 claims description 2
• IZXDFTRTTAYOMG-INIZCTEOSA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-n,n-dimethyl-2-phenylacetamide Chemical compound N([C@H](C(=O)N(C)C)C=1C=CC=CC=1)C(C(=CN=1)Cl)=NC=1NC=1C=NN(CCO)C=1 IZXDFTRTTAYOMG-INIZCTEOSA-N 0.000 claims description 2
• SZWJXPMMDUIZNT-INIZCTEOSA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-n-(2-hydroxyethyl)-2-phenylacetamide Chemical compound N([C@H](C(=O)NCCO)C=1C=CC=CC=1)C(C(=CN=1)Cl)=NC=1NC=1C=NN(CCO)C=1 SZWJXPMMDUIZNT-INIZCTEOSA-N 0.000 claims description 2
• FGDFHWKZSWVVQM-KRWDZBQOSA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-n-(2-methoxyethyl)-2-phenylacetamide Chemical compound N([C@H](C(=O)NCCOC)C=1C=CC=CC=1)C(C(=CN=1)Cl)=NC=1NC=1C=NN(CCO)C=1 FGDFHWKZSWVVQM-KRWDZBQOSA-N 0.000 claims description 2
• NKICVQQHIJMPIM-IBGZPJMESA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-n-cyclopentyl-2-phenylacetamide Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(N[C@H](C(=O)NC2CCCC2)C=2C=CC=CC=2)=N1 NKICVQQHIJMPIM-IBGZPJMESA-N 0.000 claims description 2
• DQWHPKFYJWLKBB-INIZCTEOSA-N (2s)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-n-ethyl-2-phenylacetamide Chemical compound N([C@H](C(=O)NCC)C=1C=CC=CC=1)C(C(=CN=1)Cl)=NC=1NC=1C=NN(CCO)C=1 DQWHPKFYJWLKBB-INIZCTEOSA-N 0.000 claims description 2
• MTLMXSICCGZNNV-GOSISDBHSA-N (2s)-2-[[5-chloro-2-[[1-(2-propan-2-yloxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-phenylethanol Chemical compound C1=NN(CCOC(C)C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=CC=CC=2)=N1 MTLMXSICCGZNNV-GOSISDBHSA-N 0.000 claims description 2
• DIEBUARHSHTNBW-GOSISDBHSA-N (2s)-2-[[5-fluoro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-[3-fluoro-5-(1-methylpyrazol-4-yl)phenyl]ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(F)C(N[C@H](CO)C=2C=C(C=C(F)C=2)C2=CN(C)N=C2)=N1 DIEBUARHSHTNBW-GOSISDBHSA-N 0.000 claims description 2
• NNWDPHCQEGUJRY-CQSZACIVSA-N (2s)-2-[[5-fluoro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-phenylethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(F)C(N[C@H](CO)C=2C=CC=CC=2)=N1 NNWDPHCQEGUJRY-CQSZACIVSA-N 0.000 claims description 2
• OBZKXCCWVJJJOO-LJQANCHMSA-N (2s)-2-[[5-fluoro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-[3-fluoro-5-(1-methylpyrazol-4-yl)phenyl]ethanol Chemical compound C1=NN(C)C=C1C1=CC(F)=CC([C@@H](CO)NC=2C(=CN=C(NC3=CN(CCO)N=C3)N=2)F)=C1 OBZKXCCWVJJJOO-LJQANCHMSA-N 0.000 claims description 2
• OAESFYMINDDZBR-OAHLLOKOSA-N (2s)-2-[[5-fluoro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-phenylethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(F)C(N[C@H](CO)C=2C=CC=CC=2)=N1 OAESFYMINDDZBR-OAHLLOKOSA-N 0.000 claims description 2
• MUMXWBCEQYHPQM-UHFFFAOYSA-N 1-[4-[[5-chloro-4-[[1-(2,6-difluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-2-methylpropan-2-ol Chemical compound C1=NN(CC(C)(O)C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C(=CC=CC=2F)F)=N1 MUMXWBCEQYHPQM-UHFFFAOYSA-N 0.000 claims description 2
• KLVWDWKRSPLROB-UHFFFAOYSA-N 1-[4-[[5-chloro-4-[[1-(2,6-difluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]propan-2-ol Chemical compound C1=NN(CC(O)C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C(=CC=CC=2F)F)=N1 KLVWDWKRSPLROB-UHFFFAOYSA-N 0.000 claims description 2
• YGXUTJPJGREDDU-UHFFFAOYSA-N 1-[4-[[5-chloro-4-[[1-(2-fluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-2-methylpropan-2-ol Chemical compound C1=NN(CC(C)(O)C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C(=CC=CC=2)F)=N1 YGXUTJPJGREDDU-UHFFFAOYSA-N 0.000 claims description 2
• MVHLPXLVIAEQNS-UHFFFAOYSA-N 1-[4-[[5-chloro-4-[[1-(3-fluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-2-methylpropan-2-ol Chemical compound C1=NN(CC(C)(O)C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C=C(F)C=CC=2)=N1 MVHLPXLVIAEQNS-UHFFFAOYSA-N 0.000 claims description 2
• QFMZTHIJEQORIC-UHFFFAOYSA-N 1-[4-[[5-chloro-4-[[1-(3-fluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]propan-2-ol Chemical compound C1=NN(CC(O)C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C=C(F)C=CC=2)=N1 QFMZTHIJEQORIC-UHFFFAOYSA-N 0.000 claims description 2
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 2
• NGIMWXFLGMKNKL-UHFFFAOYSA-N 2-(3-bromophenyl)-2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C=C(Br)C=CC=2)=N1 NGIMWXFLGMKNKL-UHFFFAOYSA-N 0.000 claims description 2
• MATVWFGDKHOHCG-OAHLLOKOSA-N 2-[4-[[4-[[(1s)-1-(2,5-difluorophenyl)-2-hydroxyethyl]amino]-5-fluoropyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(F)C(N[C@H](CO)C=2C(=CC=C(F)C=2)F)=N1 MATVWFGDKHOHCG-OAHLLOKOSA-N 0.000 claims description 2
• HZWHPSHPFJZOBM-OAHLLOKOSA-N 2-[4-[[4-[[(1s)-1-(3,5-difluorophenyl)-2-hydroxyethyl]amino]-5-fluoropyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(F)C(N[C@H](CO)C=2C=C(F)C=C(F)C=2)=N1 HZWHPSHPFJZOBM-OAHLLOKOSA-N 0.000 claims description 2
• DKKGOQXABNRTIZ-OAHLLOKOSA-N 2-[4-[[4-[[(1s)-1-(3-bromo-5-fluorophenyl)-2-hydroxyethyl]amino]-5-chloropyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=C(Br)C=C(F)C=2)=N1 DKKGOQXABNRTIZ-OAHLLOKOSA-N 0.000 claims description 2
• FTYABEOOWNWEFE-OAHLLOKOSA-N 2-[4-[[4-[[(1s)-1-(3-bromo-5-fluorophenyl)-2-hydroxyethyl]amino]-5-fluoropyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(F)C(N[C@H](CO)C=2C=C(Br)C=C(F)C=2)=N1 FTYABEOOWNWEFE-OAHLLOKOSA-N 0.000 claims description 2
• USGOMFLMIAOXDT-OAHLLOKOSA-N 2-[4-[[4-[[(1s)-1-(3-bromophenyl)-2-hydroxyethyl]amino]-5-chloropyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=C(Br)C=CC=2)=N1 USGOMFLMIAOXDT-OAHLLOKOSA-N 0.000 claims description 2
• SPYOWRPDXOMFTO-OAHLLOKOSA-N 2-[4-[[4-[[(1s)-1-(3-bromophenyl)-2-hydroxyethyl]amino]-5-fluoropyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(F)C(N[C@H](CO)C=2C=C(Br)C=CC=2)=N1 SPYOWRPDXOMFTO-OAHLLOKOSA-N 0.000 claims description 2
• FPXLPILAGKHEDV-QGZVFWFLSA-N 2-[4-[[4-[[(1s)-2-hydroxy-1-phenylethyl]amino]-5-methylpyrimidin-2-yl]amino]pyrazol-1-yl]-n,n-dimethylacetamide Chemical compound C1=NN(CC(=O)N(C)C)C=C1NC1=NC=C(C)C(N[C@H](CO)C=2C=CC=CC=2)=N1 FPXLPILAGKHEDV-QGZVFWFLSA-N 0.000 claims description 2
• QRTGNUWINGYOEI-MRXNPFEDSA-N 2-[4-[[4-[[(1s)-2-hydroxy-1-phenylethyl]amino]-5-methylpyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(C)C(N[C@H](CO)C=2C=CC=CC=2)=N1 QRTGNUWINGYOEI-MRXNPFEDSA-N 0.000 claims description 2
• RDJNHPLPOCUGRU-UHFFFAOYSA-N 2-[4-[[4-[[1-(2,6-difluorophenyl)-2-hydroxyethyl]amino]-5-methylpyrimidin-2-yl]amino]pyrazol-1-yl]-1-morpholin-4-ylethanone Chemical compound N1=C(NC(CO)C=2C(=CC=CC=2F)F)C(C)=CN=C1NC(=C1)C=NN1CC(=O)N1CCOCC1 RDJNHPLPOCUGRU-UHFFFAOYSA-N 0.000 claims description 2
• YGILEGKGACRRRC-MRXNPFEDSA-N 2-[4-[[5-chloro-4-[[(1r)-3-hydroxy-1-phenylpropyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(N[C@H](CCO)C=2C=CC=CC=2)=N1 YGILEGKGACRRRC-MRXNPFEDSA-N 0.000 claims description 2
• HUMUXEVIMMREDK-OAHLLOKOSA-N 2-[4-[[5-chloro-4-[[(1s)-1-(2,5-difluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C(=CC=C(F)C=2)F)=N1 HUMUXEVIMMREDK-OAHLLOKOSA-N 0.000 claims description 2
• SHEZPHYTOIDNBA-GOSISDBHSA-N 2-[4-[[5-chloro-4-[[(1s)-1-(2-fluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-1-morpholin-4-ylethanone Chemical compound N([C@H](CO)C=1C(=CC=CC=1)F)C(C(=CN=1)Cl)=NC=1NC(=C1)C=NN1CC(=O)N1CCOCC1 SHEZPHYTOIDNBA-GOSISDBHSA-N 0.000 claims description 2
• AWTYKPFGZFAAMX-OAHLLOKOSA-N 2-[4-[[5-chloro-4-[[(1s)-1-(2-fluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-2-methylpropanamide Chemical compound C1=NN(C(C)(C(N)=O)C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C(=CC=CC=2)F)=N1 AWTYKPFGZFAAMX-OAHLLOKOSA-N 0.000 claims description 2
• DAYLRTJATXIQNI-OAHLLOKOSA-N 2-[4-[[5-chloro-4-[[(1s)-1-(2-fluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C(=CC=CC=2)F)=N1 DAYLRTJATXIQNI-OAHLLOKOSA-N 0.000 claims description 2
• IKGBIPDYEDIGQC-QGZVFWFLSA-N 2-[4-[[5-chloro-4-[[(1s)-1-(2-fluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-propan-2-ylacetamide Chemical compound C1=NN(CC(=O)NC(C)C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C(=CC=CC=2)F)=N1 IKGBIPDYEDIGQC-QGZVFWFLSA-N 0.000 claims description 2
• ZLJRYJRUYVSVSG-OAHLLOKOSA-N 2-[4-[[5-chloro-4-[[(1s)-1-(3,5-difluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=C(F)C=C(F)C=2)=N1 ZLJRYJRUYVSVSG-OAHLLOKOSA-N 0.000 claims description 2
• MRYQRNALJMYYIO-GOSISDBHSA-N 2-[4-[[5-chloro-4-[[(1s)-2-hydroxy-1-(2-methoxyphenyl)ethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-1-morpholin-4-ylethanone Chemical compound COC1=CC=CC=C1[C@@H](CO)NC1=NC(NC2=CN(CC(=O)N3CCOCC3)N=C2)=NC=C1Cl MRYQRNALJMYYIO-GOSISDBHSA-N 0.000 claims description 2
• MZLRVVZENQSDRD-OAHLLOKOSA-N 2-[4-[[5-chloro-4-[[(1s)-2-hydroxy-1-(2-methoxyphenyl)ethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C(=CC=CC=2)OC)=N1 MZLRVVZENQSDRD-OAHLLOKOSA-N 0.000 claims description 2
• JIPXQCNZMBTTRN-LJQANCHMSA-N 2-[4-[[5-chloro-4-[[(1s)-2-hydroxy-1-(3-methoxyphenyl)ethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-1-morpholin-4-ylethanone Chemical compound COC1=CC=CC([C@@H](CO)NC=2C(=CN=C(NC3=CN(CC(=O)N4CCOCC4)N=C3)N=2)Cl)=C1 JIPXQCNZMBTTRN-LJQANCHMSA-N 0.000 claims description 2
• FTKYNEPIWUGBGC-MRXNPFEDSA-N 2-[4-[[5-chloro-4-[[(1s)-2-hydroxy-1-(3-methoxyphenyl)ethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=C(OC)C=CC=2)=N1 FTKYNEPIWUGBGC-MRXNPFEDSA-N 0.000 claims description 2
• IHOSXXLJIKORCO-MRXNPFEDSA-N 2-[4-[[5-chloro-4-[[(1s)-2-hydroxy-1-phenylethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n,n-dimethylacetamide Chemical compound C1=NN(CC(=O)N(C)C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=CC=CC=2)=N1 IHOSXXLJIKORCO-MRXNPFEDSA-N 0.000 claims description 2
• GPFKXICOVDFZMW-QGZVFWFLSA-N 2-[4-[[5-chloro-4-[[(1s)-2-hydroxy-1-phenylethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-(cyanomethyl)-n-methylacetamide Chemical compound C1=NN(CC(=O)N(CC#N)C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=CC=CC=2)=N1 GPFKXICOVDFZMW-QGZVFWFLSA-N 0.000 claims description 2
• BOZRKGFACHXBTC-QGZVFWFLSA-N 2-[4-[[5-chloro-4-[[(1s)-2-hydroxy-1-phenylethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-cyclopropylacetamide Chemical compound N([C@H](CO)C=1C=CC=CC=1)C(C(=CN=1)Cl)=NC=1NC(=C1)C=NN1CC(=O)NC1CC1 BOZRKGFACHXBTC-QGZVFWFLSA-N 0.000 claims description 2
• QRACHGKPVCWUJS-QGZVFWFLSA-N 2-[4-[[5-chloro-4-[[(1s)-2-hydroxy-1-phenylethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-propan-2-ylacetamide Chemical compound C1=NN(CC(=O)NC(C)C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=CC=CC=2)=N1 QRACHGKPVCWUJS-QGZVFWFLSA-N 0.000 claims description 2
• BXZRGUOBAPEQJB-CQSZACIVSA-N 2-[4-[[5-chloro-4-[[(1s)-2-hydroxy-1-phenylethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]acetic acid Chemical compound N([C@H](CO)C=1C=CC=CC=1)C(C(=CN=1)Cl)=NC=1NC=1C=NN(CC(O)=O)C=1 BXZRGUOBAPEQJB-CQSZACIVSA-N 0.000 claims description 2
• PUXWPVMRSTXHFF-QGZVFWFLSA-N 2-[4-[[5-chloro-4-[[(1s)-2-hydroxy-1-pyridin-3-ylethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-1-morpholin-4-ylethanone Chemical compound N([C@H](CO)C=1C=NC=CC=1)C(C(=CN=1)Cl)=NC=1NC(=C1)C=NN1CC(=O)N1CCOCC1 PUXWPVMRSTXHFF-QGZVFWFLSA-N 0.000 claims description 2
• UWEJVMVPKSJHKW-CQSZACIVSA-N 2-[4-[[5-chloro-4-[[(1s)-2-hydroxy-1-pyridin-3-ylethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=NC=CC=2)=N1 UWEJVMVPKSJHKW-CQSZACIVSA-N 0.000 claims description 2
• HUMUXEVIMMREDK-UHFFFAOYSA-N 2-[4-[[5-chloro-4-[[1-(2,5-difluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C(=CC=C(F)C=2)F)=N1 HUMUXEVIMMREDK-UHFFFAOYSA-N 0.000 claims description 2
• PELNHYKIWGWPBO-UHFFFAOYSA-N 2-[4-[[5-chloro-4-[[1-(2,6-difluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C(=CC=CC=2F)F)=N1 PELNHYKIWGWPBO-UHFFFAOYSA-N 0.000 claims description 2
• AQXKPRDBZPRXCH-UHFFFAOYSA-N 2-[4-[[5-chloro-4-[[1-(2-chlorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C(=CC=CC=2)Cl)=N1 AQXKPRDBZPRXCH-UHFFFAOYSA-N 0.000 claims description 2
• DAYLRTJATXIQNI-UHFFFAOYSA-N 2-[4-[[5-chloro-4-[[1-(2-fluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C(=CC=CC=2)F)=N1 DAYLRTJATXIQNI-UHFFFAOYSA-N 0.000 claims description 2
• ZLJRYJRUYVSVSG-UHFFFAOYSA-N 2-[4-[[5-chloro-4-[[1-(3,5-difluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C=C(F)C=C(F)C=2)=N1 ZLJRYJRUYVSVSG-UHFFFAOYSA-N 0.000 claims description 2
• XTAKUCIMHVOHFR-UHFFFAOYSA-N 2-[4-[[5-chloro-4-[[1-(3-fluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C=C(F)C=CC=2)=N1 XTAKUCIMHVOHFR-UHFFFAOYSA-N 0.000 claims description 2
• AFECMOMSJHWJEF-UHFFFAOYSA-N 2-[4-[[5-chloro-4-[[2-hydroxy-1-[2-(trifluoromethyl)phenyl]ethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C(=CC=CC=2)C(F)(F)F)=N1 AFECMOMSJHWJEF-UHFFFAOYSA-N 0.000 claims description 2
• HNXUEVFTQBHCDE-OAHLLOKOSA-N 2-[4-[[5-fluoro-4-[[(1s)-2-hydroxy-1-phenylethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-n-methylacetamide Chemical compound C1=NN(CC(=O)NC)C=C1NC1=NC=C(F)C(N[C@H](CO)C=2C=CC=CC=2)=N1 HNXUEVFTQBHCDE-OAHLLOKOSA-N 0.000 claims description 2
• BLCMNWHCMNPEHE-UHFFFAOYSA-N 2-[[2-[(1-methylpyrazol-4-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]-2-phenylpropan-1-ol Chemical compound C1=NN(C)C=C1NC1=NC=C(C(F)(F)F)C(NC(C)(CO)C=2C=CC=CC=2)=N1 BLCMNWHCMNPEHE-UHFFFAOYSA-N 0.000 claims description 2
• XRIZGSIEKUHTRL-UHFFFAOYSA-N 2-[[2-[[1-(2,2-difluoroethyl)pyrazol-4-yl]amino]-5-methylpyrimidin-4-yl]amino]-2-(2,6-difluorophenyl)ethanol Chemical compound N1=C(NC(CO)C=2C(=CC=CC=2F)F)C(C)=CN=C1NC=1C=NN(CC(F)F)C=1 XRIZGSIEKUHTRL-UHFFFAOYSA-N 0.000 claims description 2
• KUFAIPDLGPKRFP-UHFFFAOYSA-N 2-[[2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]-5-methylpyrimidin-4-yl]amino]-2-phenylethanol Chemical compound N1=C(NC(CO)C=2C=CC=CC=2)C(C)=CN=C1NC=1C=NN(CCO)C=1 KUFAIPDLGPKRFP-UHFFFAOYSA-N 0.000 claims description 2
• NLBLZALOYCDNAW-UHFFFAOYSA-N 2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(2,5-difluorophenyl)ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C(=CC=C(F)C=2)F)=N1 NLBLZALOYCDNAW-UHFFFAOYSA-N 0.000 claims description 2
• BPPSZYPDHVBYLR-UHFFFAOYSA-N 2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(2,6-difluorophenyl)ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C(=CC=CC=2F)F)=N1 BPPSZYPDHVBYLR-UHFFFAOYSA-N 0.000 claims description 2
• YHAKQDUQTYCBOR-UHFFFAOYSA-N 2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(2-chlorophenyl)ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C(=CC=CC=2)Cl)=N1 YHAKQDUQTYCBOR-UHFFFAOYSA-N 0.000 claims description 2
• WNAVYYSDFDNZGV-UHFFFAOYSA-N 2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(2-fluorophenyl)ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C(=CC=CC=2)F)=N1 WNAVYYSDFDNZGV-UHFFFAOYSA-N 0.000 claims description 2
• RFIUFRRMSPKJFK-UHFFFAOYSA-N 2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(3,5-difluorophenyl)ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C=C(F)C=C(F)C=2)=N1 RFIUFRRMSPKJFK-UHFFFAOYSA-N 0.000 claims description 2
• IENUHAKGQXATMC-UHFFFAOYSA-N 2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(3-fluorophenyl)ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C=C(F)C=CC=2)=N1 IENUHAKGQXATMC-UHFFFAOYSA-N 0.000 claims description 2
• HFXNLXDAQFJBDX-UHFFFAOYSA-N 2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-(4-fluorophenyl)ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C=CC(F)=CC=2)=N1 HFXNLXDAQFJBDX-UHFFFAOYSA-N 0.000 claims description 2
• DEXQVSWVAHWJPK-UHFFFAOYSA-N 2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-[3-(1-methylpyrazol-4-yl)phenyl]ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C=C(C=CC=2)C2=CN(C)N=C2)=N1 DEXQVSWVAHWJPK-UHFFFAOYSA-N 0.000 claims description 2
• HUJJMUALWOHJSQ-UHFFFAOYSA-N 2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-phenylacetic acid Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC(C(O)=O)C=2C=CC=CC=2)=N1 HUJJMUALWOHJSQ-UHFFFAOYSA-N 0.000 claims description 2
• RXQRUYJJCNKFIQ-UHFFFAOYSA-N 2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-phenylethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C=CC=CC=2)=N1 RXQRUYJJCNKFIQ-UHFFFAOYSA-N 0.000 claims description 2
• CKCSDFJODCGFLT-UHFFFAOYSA-N 2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-phenylpropan-1-ol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC(C)(CO)C=2C=CC=CC=2)=N1 CKCSDFJODCGFLT-UHFFFAOYSA-N 0.000 claims description 2
• PEJLEKFNMPWERQ-UHFFFAOYSA-N 2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-3-phenylpropan-1-ol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC(CO)CC=2C=CC=CC=2)=N1 PEJLEKFNMPWERQ-UHFFFAOYSA-N 0.000 claims description 2
• YIDFEZROOALWON-UHFFFAOYSA-N 2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-3-yl]amino]pyrimidin-4-yl]amino]-2-(2,6-difluorophenyl)ethanol Chemical compound OCCN1C=CC(NC=2N=C(NC(CO)C=3C(=CC=CC=3F)F)C(Cl)=CN=2)=N1 YIDFEZROOALWON-UHFFFAOYSA-N 0.000 claims description 2
• DYDOSUQNRBPGDA-UHFFFAOYSA-N 2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-3-yl]amino]pyrimidin-4-yl]amino]-2-(2-fluorophenyl)ethanol Chemical compound OCCN1C=CC(NC=2N=C(NC(CO)C=3C(=CC=CC=3)F)C(Cl)=CN=2)=N1 DYDOSUQNRBPGDA-UHFFFAOYSA-N 0.000 claims description 2
• PPVCISMXHZQIIT-UHFFFAOYSA-N 2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-3-yl]amino]pyrimidin-4-yl]amino]-2-(3-fluorophenyl)ethanol Chemical compound OCCN1C=CC(NC=2N=C(NC(CO)C=3C=C(F)C=CC=3)C(Cl)=CN=2)=N1 PPVCISMXHZQIIT-UHFFFAOYSA-N 0.000 claims description 2
• BKLXVHYHAOHCGE-UHFFFAOYSA-N 2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-(2,6-difluorophenyl)ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C(=CC=CC=2F)F)=N1 BKLXVHYHAOHCGE-UHFFFAOYSA-N 0.000 claims description 2
• LDNHSVKRTAUBMS-UHFFFAOYSA-N 2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-(2-chlorophenyl)ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C(=CC=CC=2)Cl)=N1 LDNHSVKRTAUBMS-UHFFFAOYSA-N 0.000 claims description 2
• SHQAXVFIOUEHHQ-UHFFFAOYSA-N 2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-(2-fluorophenyl)-n,n-dimethylacetamide Chemical compound C=1C=CC=C(F)C=1C(C(=O)N(C)C)NC(C(=CN=1)Cl)=NC=1NC=1C=NN(CCO)C=1 SHQAXVFIOUEHHQ-UHFFFAOYSA-N 0.000 claims description 2
• VLVBFDWOLPFQSL-UHFFFAOYSA-N 2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-(2-fluorophenyl)ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C(=CC=CC=2)F)=N1 VLVBFDWOLPFQSL-UHFFFAOYSA-N 0.000 claims description 2
• GZAUZHXRHFRDOK-UHFFFAOYSA-N 2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-(3,5-difluorophenyl)ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C=C(F)C=C(F)C=2)=N1 GZAUZHXRHFRDOK-UHFFFAOYSA-N 0.000 claims description 2
• CKOSHJVGYPLDMB-UHFFFAOYSA-N 2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-(3-fluorophenyl)ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C=C(F)C=CC=2)=N1 CKOSHJVGYPLDMB-UHFFFAOYSA-N 0.000 claims description 2
• HSDQSYSOTPPXKW-UHFFFAOYSA-N 2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-(4-fluorophenyl)ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C=CC(F)=CC=2)=N1 HSDQSYSOTPPXKW-UHFFFAOYSA-N 0.000 claims description 2
• IBNVHZOHLPFNTD-UHFFFAOYSA-N 2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-[3-(1-methylpyrazol-4-yl)phenyl]ethanol Chemical compound C1=NN(C)C=C1C1=CC=CC(C(CO)NC=2C(=CN=C(NC3=CN(CCO)N=C3)N=2)Cl)=C1 IBNVHZOHLPFNTD-UHFFFAOYSA-N 0.000 claims description 2
• IWBJSQDRZQXPDW-UHFFFAOYSA-N 2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-phenylacetic acid Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(NC(C(O)=O)C=2C=CC=CC=2)=N1 IWBJSQDRZQXPDW-UHFFFAOYSA-N 0.000 claims description 2
• LMRYRVSDUAONDY-UHFFFAOYSA-N 2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-3-phenylpropan-1-ol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(NC(CO)CC=2C=CC=CC=2)=N1 LMRYRVSDUAONDY-UHFFFAOYSA-N 0.000 claims description 2
• NNWDPHCQEGUJRY-UHFFFAOYSA-N 2-[[5-fluoro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-phenylethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(F)C(NC(CO)C=2C=CC=CC=2)=N1 NNWDPHCQEGUJRY-UHFFFAOYSA-N 0.000 claims description 2
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 2
• BFFOKLCANWDYEI-TZHYSIJRSA-N 3-[4-[[5-chloro-4-[[(1s)-2-hydroxy-1-phenylethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-1-methylpyrrolidin-2-one Chemical compound O=C1N(C)CCC1N1N=CC(NC=2N=C(N[C@H](CO)C=3C=CC=CC=3)C(Cl)=CN=2)=C1 BFFOKLCANWDYEI-TZHYSIJRSA-N 0.000 claims description 2
• FIHAVFRNXRCMLA-UHFFFAOYSA-N 3-[4-[[5-chloro-4-[[1-(2-fluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]propan-1-ol Chemical compound C1=NN(CCCO)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C(=CC=CC=2)F)=N1 FIHAVFRNXRCMLA-UHFFFAOYSA-N 0.000 claims description 2
• QTCMSVLPQGNMAW-OAHLLOKOSA-N 4-[3-[(1s)-1-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-hydroxyethyl]-2-fluorophenyl]morpholin-3-one Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C(=C(N3C(COCC3)=O)C=CC=2)F)=N1 QTCMSVLPQGNMAW-OAHLLOKOSA-N 0.000 claims description 2
• UIUHEIIXARGKHM-QGZVFWFLSA-N 4-[3-[(1s)-1-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-hydroxyethyl]phenyl]morpholin-3-one Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=C(C=CC=2)N2C(COCC2)=O)=N1 UIUHEIIXARGKHM-QGZVFWFLSA-N 0.000 claims description 2
• UIUHEIIXARGKHM-UHFFFAOYSA-N 4-[3-[1-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-hydroxyethyl]phenyl]morpholin-3-one Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C=C(C=CC=2)N2C(COCC2)=O)=N1 UIUHEIIXARGKHM-UHFFFAOYSA-N 0.000 claims description 2
• SFZMGXXIJQGYCY-OAHLLOKOSA-N 5-chloro-2-n-(1-methylpyrazol-4-yl)-4-n-[(1r)-1-phenylpropyl]pyrimidine-2,4-diamine Chemical compound N([C@H](CC)C=1C=CC=CC=1)C(C(=CN=1)Cl)=NC=1NC=1C=NN(C)C=1 SFZMGXXIJQGYCY-OAHLLOKOSA-N 0.000 claims description 2
• SKQPZCXHGMDQFX-OAHLLOKOSA-N 5-chloro-4-n-[(1s)-2-methoxy-1-phenylethyl]-2-n-(1-methylpyrazol-4-yl)pyrimidine-2,4-diamine Chemical compound N([C@H](COC)C=1C=CC=CC=1)C(C(=CN=1)Cl)=NC=1NC=1C=NN(C)C=1 SKQPZCXHGMDQFX-OAHLLOKOSA-N 0.000 claims description 2
• ZULKNANRYDTNQM-UHFFFAOYSA-N 5-chloro-4-n-[1-(2-fluorophenyl)propyl]-2-n-(1-methylpyrazol-4-yl)pyrimidine-2,4-diamine Chemical compound C=1C=CC=C(F)C=1C(CC)NC(C(=CN=1)Cl)=NC=1NC=1C=NN(C)C=1 ZULKNANRYDTNQM-UHFFFAOYSA-N 0.000 claims description 2
• IZNSYIUZDFSDST-GOSISDBHSA-N [4-[[5-chloro-4-[[(1s)-2-hydroxy-1-phenylethyl]amino]pyrimidin-2-yl]amino]-1h-pyrrol-2-yl]-morpholin-4-ylmethanone Chemical compound N([C@H](CO)C=1C=CC=CC=1)C(C(=CN=1)Cl)=NC=1NC(C=1)=CNC=1C(=O)N1CCOCC1 IZNSYIUZDFSDST-GOSISDBHSA-N 0.000 claims description 2
• 229910052794 bromium Inorganic materials 0.000 claims description 2
• 230000006806 disease prevention Effects 0.000 claims description 2
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 2
• JUJANQURVOHWIV-UHFFFAOYSA-N methyl 2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-phenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)OC)NC(C(=CN=1)Cl)=NC=1NC=1C=NN(C)C=1 JUJANQURVOHWIV-UHFFFAOYSA-N 0.000 claims description 2
• WGLLYVGBKSOUQO-UHFFFAOYSA-N methyl 2-[[5-chloro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-phenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)OC)NC(C(=CN=1)Cl)=NC=1NC=1C=NN(CCO)C=1 WGLLYVGBKSOUQO-UHFFFAOYSA-N 0.000 claims description 2
• 125000001624 naphthyl group Chemical group 0.000 claims description 2
• 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
• MRSQWFHDCSVGCF-CQSZACIVSA-N (2s)-2-[[5-chloro-2-[[1-(2,2-difluoroethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-2-(2-fluorophenyl)ethanol Chemical compound N([C@H](CO)C=1C(=CC=CC=1)F)C(C(=CN=1)Cl)=NC=1NC=1C=NN(CC(F)F)C=1 MRSQWFHDCSVGCF-CQSZACIVSA-N 0.000 claims 1
• XBUXORGIIBDVFL-GOSISDBHSA-N 2-[4-[[5-fluoro-4-[[(1s)-2-hydroxy-1-phenylethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]-1-morpholin-4-ylethanone Chemical compound N([C@H](CO)C=1C=CC=CC=1)C(C(=CN=1)F)=NC=1NC(=C1)C=NN1CC(=O)N1CCOCC1 XBUXORGIIBDVFL-GOSISDBHSA-N 0.000 claims 1
• 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
• 238000002360 preparation method Methods 0.000 abstract description 17
• 230000001404 mediated effect Effects 0.000 abstract description 6
• 230000002265 prevention Effects 0.000 abstract description 5
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
• 239000000243 solution Substances 0.000 description 45
• 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 43
• 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 42
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 42
• 239000000203 mixture Substances 0.000 description 37
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 34
• 239000011541 reaction mixture Substances 0.000 description 34
• 210000004027 cell Anatomy 0.000 description 31
• 102000015617 Janus Kinases Human genes 0.000 description 30
• 108010024121 Janus Kinases Proteins 0.000 description 30
• 239000007787 solid Substances 0.000 description 28
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
• 206010028980 Neoplasm Diseases 0.000 description 21
• 239000000872 buffer Substances 0.000 description 20
• 230000000694 effects Effects 0.000 description 19
• 201000011510 cancer Diseases 0.000 description 18
• 238000012360 testing method Methods 0.000 description 18
• 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 17
• 235000019439 ethyl acetate Nutrition 0.000 description 17
• 108090000623 proteins and genes Proteins 0.000 description 17
• 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 16
• 230000015572 biosynthetic process Effects 0.000 description 16
• 239000003112 inhibitor Substances 0.000 description 16
• 125000001424 substituent group Chemical group 0.000 description 16
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
• 238000003786 synthesis reaction Methods 0.000 description 15
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 14
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
• 239000000047 product Substances 0.000 description 13
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
• 108091000080 Phosphotransferase Proteins 0.000 description 12
• 239000003795 chemical substances by application Substances 0.000 description 12
• 102000020233 phosphotransferase Human genes 0.000 description 12
• 108090000695 Cytokines Proteins 0.000 description 11
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
• 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 11
• 102000004169 proteins and genes Human genes 0.000 description 11
• 238000005160 1H NMR spectroscopy Methods 0.000 description 10
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
• 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 10
• 239000012267 brine Substances 0.000 description 10
• 238000006243 chemical reaction Methods 0.000 description 10
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 10
• 206010039073 rheumatoid arthritis Diseases 0.000 description 10
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 9
• 102000004127 Cytokines Human genes 0.000 description 9
• 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 9
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
• 239000002552 dosage form Substances 0.000 description 9
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
• 239000002244 precipitate Substances 0.000 description 9
• 239000000725 suspension Substances 0.000 description 9
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 8
• 206010013774 Dry eye Diseases 0.000 description 8
• 239000007821 HATU Substances 0.000 description 8
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
• 206010061218 Inflammation Diseases 0.000 description 8
• 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 102000015774 TYK2 Kinase Human genes 0.000 description 8
• 108010010057 TYK2 Kinase Proteins 0.000 description 8
• 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 8
• 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 8
• 238000003556 assay Methods 0.000 description 8
• 239000011324 bead Substances 0.000 description 8
• 238000003818 flash chromatography Methods 0.000 description 8
• 239000001257 hydrogen Substances 0.000 description 8
• 230000004054 inflammatory process Effects 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• 239000007788 liquid Substances 0.000 description 8
• 239000012528 membrane Substances 0.000 description 8
• 238000000746 purification Methods 0.000 description 8
• 239000002904 solvent Substances 0.000 description 8
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 7
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 7
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 7
• 108010002350 Interleukin-2 Proteins 0.000 description 7
• 102000000588 Interleukin-2 Human genes 0.000 description 7
• 230000004913 activation Effects 0.000 description 7
• 239000004480 active ingredient Substances 0.000 description 7
• 150000001408 amides Chemical class 0.000 description 7
• 230000001684 chronic effect Effects 0.000 description 7
• 238000001514 detection method Methods 0.000 description 7
• 239000000706 filtrate Substances 0.000 description 7
• 238000001914 filtration Methods 0.000 description 7
• 235000019253 formic acid Nutrition 0.000 description 7
• 230000014509 gene expression Effects 0.000 description 7
• 235000011187 glycerol Nutrition 0.000 description 7
• 239000006166 lysate Substances 0.000 description 7
• 230000035772 mutation Effects 0.000 description 7
• 239000012044 organic layer Substances 0.000 description 7
• 102000005962 receptors Human genes 0.000 description 7
• 108020003175 receptors Proteins 0.000 description 7
• 239000000758 substrate Substances 0.000 description 7
• 238000004704 ultra performance liquid chromatography Methods 0.000 description 7
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 210000001744 T-lymphocyte Anatomy 0.000 description 6
• 230000002159 abnormal effect Effects 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 239000013592 cell lysate Substances 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
• 229960005419 nitrogen Drugs 0.000 description 6
• 210000000056 organ Anatomy 0.000 description 6
• 125000006413 ring segment Chemical group 0.000 description 6
• 208000023275 Autoimmune disease Diseases 0.000 description 5
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• 150000001412 amines Chemical class 0.000 description 5
• 150000001499 aryl bromides Chemical class 0.000 description 5
• 150000003939 benzylamines Chemical class 0.000 description 5
• 239000002775 capsule Substances 0.000 description 5
• 125000004432 carbon atom Chemical group C* 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 230000010261 cell growth Effects 0.000 description 5
• 235000019441 ethanol Nutrition 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 210000003630 histaminocyte Anatomy 0.000 description 5
• 208000027866 inflammatory disease Diseases 0.000 description 5
• 201000006417 multiple sclerosis Diseases 0.000 description 5
• 239000003208 petroleum Substances 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 230000002441 reversible effect Effects 0.000 description 5
• 230000011664 signaling Effects 0.000 description 5
• 239000011734 sodium Substances 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• ZZZXGANTRBHRTJ-SNVBAGLBSA-N (2s)-2-[(2,5-dichloropyrimidin-4-yl)amino]-2-phenylethanol Chemical compound N([C@H](CO)C=1C=CC=CC=1)C1=NC(Cl)=NC=C1Cl ZZZXGANTRBHRTJ-SNVBAGLBSA-N 0.000 description 4
• GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 4
• XORHNJQEWQGXCN-UHFFFAOYSA-N 4-nitro-1h-pyrazole Chemical compound [O-][N+](=O)C=1C=NNC=1 XORHNJQEWQGXCN-UHFFFAOYSA-N 0.000 description 4
• 206010009900 Colitis ulcerative Diseases 0.000 description 4
• 208000011231 Crohn disease Diseases 0.000 description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
• 239000012981 Hank's balanced salt solution Substances 0.000 description 4
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
• 102000001253 Protein Kinase Human genes 0.000 description 4
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
• 201000006704 Ulcerative Colitis Diseases 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 239000000556 agonist Substances 0.000 description 4
• WGQKYBSKWIADBV-UHFFFAOYSA-N aminomethyl benzene Natural products NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
• 229910021529 ammonia Inorganic materials 0.000 description 4
• 230000006378 damage Effects 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 description 4
• KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 235000019198 oils Nutrition 0.000 description 4
• 239000012074 organic phase Substances 0.000 description 4
• 229910052760 oxygen Inorganic materials 0.000 description 4
• 239000012071 phase Substances 0.000 description 4
• 238000006366 phosphorylation reaction Methods 0.000 description 4
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
• 108060006633 protein kinase Proteins 0.000 description 4
• 150000003230 pyrimidines Chemical class 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 4
• 239000000523 sample Substances 0.000 description 4
• 230000019491 signal transduction Effects 0.000 description 4
• 239000005720 sucrose Substances 0.000 description 4
• 229910052717 sulfur Inorganic materials 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
• 238000002054 transplantation Methods 0.000 description 4
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 4
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 4
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
• 108010036949 Cyclosporine Proteins 0.000 description 3
• 201000004624 Dermatitis Diseases 0.000 description 3
• 102000001301 EGF receptor Human genes 0.000 description 3
• 108060006698 EGF receptor Proteins 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 229920001213 Polysorbate 20 Polymers 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
• 206010046851 Uveitis Diseases 0.000 description 3
• 230000002378 acidificating effect Effects 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 125000003342 alkenyl group Chemical group 0.000 description 3
• 238000003016 alphascreen Methods 0.000 description 3
• 229940024606 amino acid Drugs 0.000 description 3
• 150000001413 amino acids Chemical class 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 230000020411 cell activation Effects 0.000 description 3
• 239000008004 cell lysis buffer Substances 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 210000000349 chromosome Anatomy 0.000 description 3
• 229960001265 ciclosporin Drugs 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 210000001072 colon Anatomy 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
• 239000012458 free base Substances 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• 125000001183 hydrocarbyl group Chemical group 0.000 description 3
• 229940125721 immunosuppressive agent Drugs 0.000 description 3
• 239000003018 immunosuppressive agent Substances 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 210000004185 liver Anatomy 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 239000002207 metabolite Substances 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 239000001301 oxygen Substances 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 230000026731 phosphorylation Effects 0.000 description 3
• 239000006187 pill Substances 0.000 description 3
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 239000011593 sulfur Substances 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 230000004393 visual impairment Effects 0.000 description 3
• 239000003643 water by type Substances 0.000 description 3
• APGOHCBEJDAUOM-VYIIXAMBSA-N (2S)-2-amino-N-(1-diphenoxyphosphorylethyl)butanediamide Chemical compound C=1C=CC=CC=1OP(=O)(C(NC(=O)[C@@H](N)CC(N)=O)C)OC1=CC=CC=C1 APGOHCBEJDAUOM-VYIIXAMBSA-N 0.000 description 2
• JFDIXHFQHJSWNM-SNVBAGLBSA-N (2s)-2-[(2,5-dichloropyrimidin-4-yl)amino]-2-(2-fluorophenyl)ethanol Chemical compound N([C@H](CO)C=1C(=CC=CC=1)F)C1=NC(Cl)=NC=C1Cl JFDIXHFQHJSWNM-SNVBAGLBSA-N 0.000 description 2
• IJXJGQCXFSSHNL-MRVPVSSYSA-N (2s)-2-amino-2-phenylethanol Chemical compound OC[C@@H](N)C1=CC=CC=C1 IJXJGQCXFSSHNL-MRVPVSSYSA-N 0.000 description 2
• HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 2
• 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 description 2
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
• UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
• FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
• AXINVSXSGNSVLV-UHFFFAOYSA-N 1h-pyrazol-4-amine Chemical class NC=1C=NNC=1 AXINVSXSGNSVLV-UHFFFAOYSA-N 0.000 description 2
• MAVOONNUTMUHHG-UHFFFAOYSA-N 2-(4-aminopyrazol-1-yl)acetamide Chemical compound NC(=O)CN1C=C(N)C=N1 MAVOONNUTMUHHG-UHFFFAOYSA-N 0.000 description 2
• MVTANXJTPWHBTC-UHFFFAOYSA-N 2-(4-nitropyrazol-1-yl)acetamide Chemical compound NC(=O)CN1C=C([N+]([O-])=O)C=N1 MVTANXJTPWHBTC-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
• BXVSAYBZSGIURM-UHFFFAOYSA-N 2-phenoxy-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide Chemical compound O1CC2=CC=CC=C2OP1(=O)OC1=CC=CC=C1 BXVSAYBZSGIURM-UHFFFAOYSA-N 0.000 description 2
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
• HOZUXBLMYUPGPZ-UHFFFAOYSA-N 4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C=C1 HOZUXBLMYUPGPZ-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 102000009465 Growth Factor Receptors Human genes 0.000 description 2
• 108010009202 Growth Factor Receptors Proteins 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
• WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 2
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
• 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
• 102000004388 Interleukin-4 Human genes 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
• 208000014767 Myeloproliferative disease Diseases 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• 239000000020 Nitrocellulose Substances 0.000 description 2
• ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 108010029477 STAT5 Transcription Factor Proteins 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
• 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 2
• 208000024780 Urticaria Diseases 0.000 description 2
• 206010047571 Visual impairment Diseases 0.000 description 2
• 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 2
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
• 208000017733 acquired polycythemia vera Diseases 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 230000002152 alkylating effect Effects 0.000 description 2
• 230000000735 allogeneic effect Effects 0.000 description 2
• 229960004238 anakinra Drugs 0.000 description 2
• 208000003455 anaphylaxis Diseases 0.000 description 2
• 239000004037 angiogenesis inhibitor Substances 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 230000000340 anti-metabolite Effects 0.000 description 2
• 230000000692 anti-sense effect Effects 0.000 description 2
• 229940100197 antimetabolite Drugs 0.000 description 2
• 239000002256 antimetabolite Substances 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 239000003435 antirheumatic agent Substances 0.000 description 2
• 239000008346 aqueous phase Substances 0.000 description 2
• 125000003118 aryl group Chemical group 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• 238000004166 bioassay Methods 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 238000010322 bone marrow transplantation Methods 0.000 description 2
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
• 229910000024 caesium carbonate Inorganic materials 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 229960004630 chlorambucil Drugs 0.000 description 2
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• 208000037976 chronic inflammation Diseases 0.000 description 2
• 238000001816 cooling Methods 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
• 229930182912 cyclosporin Natural products 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 229940127089 cytotoxic agent Drugs 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
• 239000007884 disintegrant Substances 0.000 description 2
• 229960001433 erlotinib Drugs 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 208000030533 eye disease Diseases 0.000 description 2
• 239000012065 filter cake Substances 0.000 description 2
• 125000001153 fluoro group Chemical group F* 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 description 2
• KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
• 208000035474 group of disease Diseases 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 210000002865 immune cell Anatomy 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
• 206010023332 keratitis Diseases 0.000 description 2
• 201000010666 keratoconjunctivitis Diseases 0.000 description 2
• 229940043355 kinase inhibitor Drugs 0.000 description 2
• 238000011813 knockout mouse model Methods 0.000 description 2
• 239000004310 lactic acid Substances 0.000 description 2
• 235000014655 lactic acid Nutrition 0.000 description 2
• 229960000681 leflunomide Drugs 0.000 description 2
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 239000003475 metalloproteinase inhibitor Substances 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• GEADOFDFVOSIOA-UHFFFAOYSA-N methyl 2-(4-nitropyrazol-1-yl)acetate Chemical compound COC(=O)CN1C=C([N+]([O-])=O)C=N1 GEADOFDFVOSIOA-UHFFFAOYSA-N 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• WMLQHWGCESQYGM-UHFFFAOYSA-N n-methyl-2-(4-nitropyrazol-1-yl)acetamide Chemical compound CNC(=O)CN1C=C([N+]([O-])=O)C=N1 WMLQHWGCESQYGM-UHFFFAOYSA-N 0.000 description 2
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 210000003928 nasal cavity Anatomy 0.000 description 2
• 210000000440 neutrophil Anatomy 0.000 description 2
• 229920001220 nitrocellulos Polymers 0.000 description 2
• 125000004433 nitrogen atom Chemical group N* 0.000 description 2
• 125000006574 non-aromatic ring group Chemical group 0.000 description 2
• 239000006186 oral dosage form Substances 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 229910052763 palladium Inorganic materials 0.000 description 2
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
• WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
• 208000037244 polycythemia vera Diseases 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 229910000027 potassium carbonate Inorganic materials 0.000 description 2
• 238000000634 powder X-ray diffraction Methods 0.000 description 2
• 238000002953 preparative HPLC Methods 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 229940002612 prodrug Drugs 0.000 description 2
• 239000000651 prodrug Substances 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
• 230000000306 recurrent effect Effects 0.000 description 2
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 2
• 239000000377 silicon dioxide Substances 0.000 description 2
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
• 229960002930 sirolimus Drugs 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 239000002002 slurry Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 238000003419 tautomerization reaction Methods 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 150000003536 tetrazoles Chemical class 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 238000002411 thermogravimetry Methods 0.000 description 2
• VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
• 229930192474 thiophene Natural products 0.000 description 2
• UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 150000003852 triazoles Chemical class 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 208000029257 vision disease Diseases 0.000 description 2
• RJNRORZRFGUAKL-ADMBVFOFSA-N (1r)-1-[(3ar,5r,6s,6ar)-6-[3-(dimethylamino)propoxy]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]ethane-1,2-diol;hydrochloride Chemical compound Cl.O1C(C)(C)O[C@@H]2[C@@H](OCCCN(C)C)[C@@H]([C@H](O)CO)O[C@@H]21 RJNRORZRFGUAKL-ADMBVFOFSA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• YOLVBJUSDXESQT-LSLKUGRBSA-N (2S)-2-amino-N-(1-diphenoxyphosphorylethyl)propanamide Chemical compound C=1C=CC=CC=1OP(=O)(C(C)NC(=O)[C@@H](N)C)OC1=CC=CC=C1 YOLVBJUSDXESQT-LSLKUGRBSA-N 0.000 description 1
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
• VRCADXNOODMAKS-OAHLLOKOSA-N (2s)-2-(2,5-difluorophenyl)-2-[[5-fluoro-2-[[1-(2-hydroxyethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(F)C(N[C@H](CO)C=2C(=CC=C(F)C=2)F)=N1 VRCADXNOODMAKS-OAHLLOKOSA-N 0.000 description 1
• ZGRDJXDWQGTWBF-CQSZACIVSA-N (2s)-2-(3-bromo-5-fluorophenyl)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=C(Br)C=C(F)C=2)=N1 ZGRDJXDWQGTWBF-CQSZACIVSA-N 0.000 description 1
• HOBFSNNENNQQIU-JTQLQIEISA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-2-phenylacetic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)C1=CC=CC=C1 HOBFSNNENNQQIU-JTQLQIEISA-N 0.000 description 1
• CDIGVRQLUFGRRZ-CYBMUJFWSA-N (2s)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-pyridin-3-ylethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C=NC=CC=2)=N1 CDIGVRQLUFGRRZ-CYBMUJFWSA-N 0.000 description 1
• FHUUTFIWBXUNPK-DDWIOCJRSA-N (2s)-2-amino-2-(2-fluorophenyl)ethanol;hydrochloride Chemical compound Cl.OC[C@@H](N)C1=CC=CC=C1F FHUUTFIWBXUNPK-DDWIOCJRSA-N 0.000 description 1
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 1
• WKLKKBHKLVIRSD-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline 1,2,3,4-tetrahydroquinoline Chemical compound C1CCC2NCCCC2C1.C1CNc2ccccc2C1 WKLKKBHKLVIRSD-UHFFFAOYSA-N 0.000 description 1
• CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
• KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
• IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 1
• IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 1
• CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
• CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 1
• BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
• OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
• FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 description 1
• KPKNTUUIEVXMOH-UHFFFAOYSA-N 1,4-dioxa-8-azaspiro[4.5]decane Chemical compound O1CCOC11CCNCC1 KPKNTUUIEVXMOH-UHFFFAOYSA-N 0.000 description 1
• WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
• DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
• UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 1
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
• ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
• 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
• WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 1
• CANMIUFARMZZQH-UHFFFAOYSA-N 2-(3-bromophenyl)-2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C=C(Br)C=CC=2)=N1 CANMIUFARMZZQH-UHFFFAOYSA-N 0.000 description 1
• FRUYIVIAILMCPE-UHFFFAOYSA-N 2-(4-aminopyrazol-1-yl)-n-methylacetamide Chemical compound CNC(=O)CN1C=C(N)C=N1 FRUYIVIAILMCPE-UHFFFAOYSA-N 0.000 description 1
• OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
• IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
• KYRHJOKUNWBAGC-UHFFFAOYSA-N 2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-2-[3-(2-oxa-6-azaspiro[3.3]heptan-6-yl)phenyl]ethanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC(CO)C=2C=C(C=CC=2)N2CC3(COC3)C2)=N1 KYRHJOKUNWBAGC-UHFFFAOYSA-N 0.000 description 1
• UNCQVRBWJWWJBF-UHFFFAOYSA-N 2-chloropyrimidine Chemical compound ClC1=NC=CC=N1 UNCQVRBWJWWJBF-UHFFFAOYSA-N 0.000 description 1
• ZSMYDXTVVJUKCU-UHFFFAOYSA-N 2-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical compound C=1C2=NC(OC)=NC=C2C=CC=1OCCCN1CCCC1 ZSMYDXTVVJUKCU-UHFFFAOYSA-N 0.000 description 1
• RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
• MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 description 1
• GUUULVAMQJLDSY-UHFFFAOYSA-N 4,5-dihydro-1,2-thiazole Chemical compound C1CC=NS1 GUUULVAMQJLDSY-UHFFFAOYSA-N 0.000 description 1
• WEDKTMOIKOKBSH-UHFFFAOYSA-N 4,5-dihydrothiadiazole Chemical compound C1CN=NS1 WEDKTMOIKOKBSH-UHFFFAOYSA-N 0.000 description 1
• XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
• SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
• MZRUFMBFIKGOAL-UHFFFAOYSA-N 5-nitro-1h-pyrazole Chemical class [O-][N+](=O)C1=CC=NN1 MZRUFMBFIKGOAL-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical compound C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 description 1
• 230000035502 ADME Effects 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 206010002199 Anaphylactic shock Diseases 0.000 description 1
• 208000028185 Angioedema Diseases 0.000 description 1
• 102000012936 Angiostatins Human genes 0.000 description 1
• 108010079709 Angiostatins Proteins 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• SHGCHFMGUBHIJY-UHFFFAOYSA-N B(O)O.CC1=NNC=C1 Chemical compound B(O)O.CC1=NNC=C1 SHGCHFMGUBHIJY-UHFFFAOYSA-N 0.000 description 1
• 230000003844 B-cell-activation Effects 0.000 description 1
• 102000052609 BRCA2 Human genes 0.000 description 1
• 108700020462 BRCA2 Proteins 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 241000167854 Bourreria succulenta Species 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 238000009010 Bradford assay Methods 0.000 description 1
• 101150008921 Brca2 gene Proteins 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 108010037003 Buserelin Proteins 0.000 description 1
• 0 Cc1c[n](*)nc1 Chemical compound Cc1c[n](*)nc1 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 206010010099 Combined immunodeficiency Diseases 0.000 description 1
• HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• 102000000311 Cytosine Deaminase Human genes 0.000 description 1
• 108010080611 Cytosine Deaminase Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
• NTURVSFTOYPGON-UHFFFAOYSA-N Dihydroquinazoline Chemical compound C1=CC=C2C=NCNC2=C1 NTURVSFTOYPGON-UHFFFAOYSA-N 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 102400001368 Epidermal growth factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 102100038595 Estrogen receptor Human genes 0.000 description 1
• 108010008165 Etanercept Proteins 0.000 description 1
• 206010073306 Exposure to radiation Diseases 0.000 description 1
• 102100020903 Ezrin Human genes 0.000 description 1
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
• 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 108010091824 Focal Adhesion Kinase 1 Proteins 0.000 description 1
• 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 1
• VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
• 230000005526 G1 to G0 transition Effects 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
• 108010069236 Goserelin Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 206010019755 Hepatitis chronic active Diseases 0.000 description 1
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
• 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
• 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
• 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
• 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
• 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
• 102000003815 Interleukin-11 Human genes 0.000 description 1
• 108090000177 Interleukin-11 Proteins 0.000 description 1
• 102000003812 Interleukin-15 Human genes 0.000 description 1
• 108090000172 Interleukin-15 Proteins 0.000 description 1
• 102100030703 Interleukin-22 Human genes 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 102100021592 Interleukin-7 Human genes 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 102000000585 Interleukin-9 Human genes 0.000 description 1
• 241000764238 Isis Species 0.000 description 1
• 102000042838 JAK family Human genes 0.000 description 1
• 108091082332 JAK family Proteins 0.000 description 1
• 101150009057 JAK2 gene Proteins 0.000 description 1
• 108010000837 Janus Kinase 1 Proteins 0.000 description 1
• 108010019437 Janus Kinase 2 Proteins 0.000 description 1
• 108010019421 Janus Kinase 3 Proteins 0.000 description 1
• 229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 1
• 208000022120 Jeavons syndrome Diseases 0.000 description 1
• 102000001399 Kallikrein Human genes 0.000 description 1
• 108060005987 Kallikrein Proteins 0.000 description 1
• 229930194542 Keto Natural products 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
• 102100027869 Moesin Human genes 0.000 description 1
• 101100346764 Mus musculus Mtln gene Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• QECVIPBZOPUTRD-UHFFFAOYSA-N N=S(=O)=O Chemical class N=S(=O)=O QECVIPBZOPUTRD-UHFFFAOYSA-N 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 102000004459 Nitroreductase Human genes 0.000 description 1
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 241001111421 Pannus Species 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
• 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
• 101710196266 Protein 4.1 Proteins 0.000 description 1
• 102100031952 Protein 4.1 Human genes 0.000 description 1
• 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
• 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 102100022127 Radixin Human genes 0.000 description 1
• 238000001237 Raman spectrum Methods 0.000 description 1
• 108091005682 Receptor kinases Proteins 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 108060006706 SRC Proteins 0.000 description 1
• 102000001332 SRC Human genes 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 206010045240 Type I hypersensitivity Diseases 0.000 description 1
• 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
• 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 229940122803 Vinca alkaloid Drugs 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 229960003697 abatacept Drugs 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 235000011054 acetic acid Nutrition 0.000 description 1
• 239000012346 acetyl chloride Substances 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 229960002964 adalimumab Drugs 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• 201000009961 allergic asthma Diseases 0.000 description 1
• 208000002205 allergic conjunctivitis Diseases 0.000 description 1
• 230000009285 allergic inflammation Effects 0.000 description 1
• 201000010435 allergic urticaria Diseases 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 125000003368 amide group Chemical group 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 229960001220 amsacrine Drugs 0.000 description 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 229960002932 anastrozole Drugs 0.000 description 1
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 238000005349 anion exchange Methods 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000002280 anti-androgenic effect Effects 0.000 description 1
• 229940046836 anti-estrogen Drugs 0.000 description 1
• 230000001833 anti-estrogenic effect Effects 0.000 description 1
• 230000003432 anti-folate effect Effects 0.000 description 1
• 230000002942 anti-growth Effects 0.000 description 1
• 230000001740 anti-invasion Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 239000000051 antiandrogen Substances 0.000 description 1
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940127074 antifolate Drugs 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000003886 aromatase inhibitor Substances 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 239000000607 artificial tear Substances 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
• 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• 229940120638 avastin Drugs 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
• HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 239000002585 base Substances 0.000 description 1
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
• MXMZCLLIUQEKSN-UHFFFAOYSA-N benzimidazoline Chemical compound C1=CC=C2NCNC2=C1 MXMZCLLIUQEKSN-UHFFFAOYSA-N 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 229960003237 betaine Drugs 0.000 description 1
• 229960000397 bevacizumab Drugs 0.000 description 1
• 229960000997 bicalutamide Drugs 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• BGECDVWSWDRFSP-UHFFFAOYSA-N borazine Chemical compound B1NBNBN1 BGECDVWSWDRFSP-UHFFFAOYSA-N 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
• CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
• 229960002719 buserelin Drugs 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 229950002826 canertinib Drugs 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 238000005341 cation exchange Methods 0.000 description 1
• 229960002412 cediranib Drugs 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 230000011712 cell development Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000036978 cell physiology Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 235000019693 cherries Nutrition 0.000 description 1
• VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 230000000112 colonic effect Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 125000006165 cyclic alkyl group Chemical group 0.000 description 1
• 125000000753 cycloalkyl group Chemical group 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
• 229960000978 cyproterone acetate Drugs 0.000 description 1
• UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 230000003210 demyelinating effect Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 210000004207 dermis Anatomy 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 1
• 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
• 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 1
• 238000000113 differential scanning calorimetry Methods 0.000 description 1
• 239000013024 dilution buffer Substances 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 229950004203 droloxifene Drugs 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 210000001513 elbow Anatomy 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 231100001129 embryonic lethality Toxicity 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 150000002085 enols Chemical group 0.000 description 1
• 229940088598 enzyme Drugs 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 230000010437 erythropoiesis Effects 0.000 description 1
• 239000000328 estrogen antagonist Substances 0.000 description 1
• 108010038795 estrogen receptors Proteins 0.000 description 1
• 229960000403 etanercept Drugs 0.000 description 1
• PWJOFLJKTWORKR-UHFFFAOYSA-N ethyl 2-(4-aminopyrazol-1-yl)acetate Chemical compound CCOC(=O)CN1C=C(N)C=N1 PWJOFLJKTWORKR-UHFFFAOYSA-N 0.000 description 1
• XQNXEEZUFNEXOS-MRXNPFEDSA-N ethyl 2-[4-[[5-chloro-4-[[(1s)-1-(2-fluorophenyl)-2-hydroxyethyl]amino]pyrimidin-2-yl]amino]pyrazol-1-yl]acetate Chemical compound C1=NN(CC(=O)OCC)C=C1NC1=NC=C(Cl)C(N[C@H](CO)C=2C(=CC=CC=2)F)=N1 XQNXEEZUFNEXOS-MRXNPFEDSA-N 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 229960000255 exemestane Drugs 0.000 description 1
• 108010055671 ezrin Proteins 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
• 229960004039 finasteride Drugs 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 150000005699 fluoropyrimidines Chemical class 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 239000004052 folic acid antagonist Substances 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 229960002258 fulvestrant Drugs 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229960002989 glutamic acid Drugs 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 229940015045 gold sodium thiomalate Drugs 0.000 description 1
• XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
• 229960002913 goserelin Drugs 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000003979 granulating agent Substances 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 239000007902 hard capsule Substances 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• 210000003917 human chromosome Anatomy 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229960003160 hyaluronic acid Drugs 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
• 229960004171 hydroxychloroquine Drugs 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 210000003405 ileum Anatomy 0.000 description 1
• 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 239000005414 inactive ingredient Substances 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 229960000598 infliximab Drugs 0.000 description 1
• 238000003331 infrared imaging Methods 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 238000012739 integrated shape imaging system Methods 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 229940074383 interleukin-11 Drugs 0.000 description 1
• 108010074108 interleukin-21 Proteins 0.000 description 1
• 229940028885 interleukin-4 Drugs 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 238000001948 isotopic labelling Methods 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 125000000468 ketone group Chemical group 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 229960004891 lapatinib Drugs 0.000 description 1
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
• 239000010410 layer Substances 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 229960003881 letrozole Drugs 0.000 description 1
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
• 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 239000003120 macrolide antibiotic agent Substances 0.000 description 1
• 229940041033 macrolides Drugs 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 235000014380 magnesium carbonate Nutrition 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
• 229950008959 marimastat Drugs 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960004296 megestrol acetate Drugs 0.000 description 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• QABLOFMHHSOFRJ-UHFFFAOYSA-N methyl 2-chloroacetate Chemical compound COC(=O)CCl QABLOFMHHSOFRJ-UHFFFAOYSA-N 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
• 230000000116 mitigating effect Effects 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 229950000844 mizoribine Drugs 0.000 description 1
• 108010071525 moesin Proteins 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
• PGJWRLRUZXKWQX-UHFFFAOYSA-N n-benzyl-2,5-dichloropyrimidin-4-amine Chemical compound ClC1=CN=C(Cl)N=C1NCC1=CC=CC=C1 PGJWRLRUZXKWQX-UHFFFAOYSA-N 0.000 description 1
• WADKWFHHPPUKBC-UHFFFAOYSA-N n-benzyl-2-chloro-5-fluoropyrimidin-4-amine Chemical compound FC1=CN=C(Cl)N=C1NCC1=CC=CC=C1 WADKWFHHPPUKBC-UHFFFAOYSA-N 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 229960002653 nilutamide Drugs 0.000 description 1
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 108020001162 nitroreductase Proteins 0.000 description 1
• 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
• 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 229960001639 penicillamine Drugs 0.000 description 1
• 230000009984 peri-natal effect Effects 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229960003171 plicamycin Drugs 0.000 description 1
• 208000030428 polyarticular arthritis Diseases 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 239000004417 polycarbonate Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 229940076372 protein antagonist Drugs 0.000 description 1
• 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
• CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
• DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
• PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• WZUYRUCXPBGUOM-UHFFFAOYSA-N pyrido[3,2-d]pyrimidin-2-amine Chemical compound N1=CC=CC2=NC(N)=NC=C21 WZUYRUCXPBGUOM-UHFFFAOYSA-N 0.000 description 1
• ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 1
• JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 108010048484 radixin Proteins 0.000 description 1
• 229960004622 raloxifene Drugs 0.000 description 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
• 229920005604 random copolymer Polymers 0.000 description 1
• 230000007420 reactivation Effects 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 235000020095 red wine Nutrition 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
• 229960001487 rimexolone Drugs 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• 229960003522 roquinimex Drugs 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 229950009919 saracatinib Drugs 0.000 description 1
• 210000004761 scalp Anatomy 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 230000007781 signaling event Effects 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 229940126586 small molecule drug Drugs 0.000 description 1
• CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
• 229960001796 sunitinib Drugs 0.000 description 1
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 210000001258 synovial membrane Anatomy 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229940126703 systemic medication Drugs 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229940063683 taxotere Drugs 0.000 description 1
• 229960001674 tegafur Drugs 0.000 description 1
• WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• RXTKSYUIDWDWTH-UHFFFAOYSA-N tert-butyl n-(aminomethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCN RXTKSYUIDWDWTH-UHFFFAOYSA-N 0.000 description 1
• RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
• RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical compound C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 description 1
• CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
• XSROQCDVUIHRSI-UHFFFAOYSA-N thietane Chemical compound C1CSC1 XSROQCDVUIHRSI-UHFFFAOYSA-N 0.000 description 1
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• 229960005026 toremifene Drugs 0.000 description 1
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
• 108091006106 transcriptional activators Proteins 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 238000005199 ultracentrifugation Methods 0.000 description 1
• 230000004222 uncontrolled growth Effects 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 229960000241 vandetanib Drugs 0.000 description 1
• 229950000578 vatalanib Drugs 0.000 description 1
• YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• 239000011534 wash buffer Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 229910000166 zirconium phosphate Inorganic materials 0.000 description 1